Short-term quality of life after myomectomy for uterine fibroids from the COMPARE-UF Fibroid Registry

Abstract

BACKGROUND: Uterine fibroids may decrease quality of life in a significant proportion of affected women. Myomectomy offers a uterinesparing treatment option for patients with uterine fibroids that can be performed abdominally, laparoscopically (with or without robotic assistance), and hysteroscopically. Quality of life information using validated measures for different myomectomy routes, especially hysteroscopic myomectomy, is limited. OBJECTIVE: To compare women's perception of their short-term health-related quality of life measures and reported time to return to usual activities and return to work for different routes of myomectomy. MATERIALS AND METHODS: Comparing Options for Management: Patient-centered Results for Uterine Fibroids (COMPARE-UF) is a prospective nationwide fibroid registry that enrolled premenopausal women seeking treatment for uterine fibroids at 8 clinical sites. For this analysis, we included women undergoing hysteroscopic, abdominal, or laparoscopic myomectomy who completed the postprocedure questionnaire scheduled between 6 and 12 weeks after surgery. Health-related quality of life outcomes, such as pain, anxiety, and return to usual activitie, were assessed for each route. The hysteroscopic myomectomy group had large differences in demographics, fibroid number, and uterine size compared to the other groups; thus, a direct comparison of quality of life measures was performed only for abdominal and laparoscopic approaches after propensity weighting. Propensity weighting was done using 24 variables that included demographics, quality of life baseline measures, and fibroid and uterine measurements. RESULTS: A total of 1206 women from 8 COMPARE-UF sites underwent myomectomy (338 hysteroscopic, 519 laparoscopic, and 349 abdominal). All women had substantial improvement in short-term health-related quality of life and symptom severity scores, which was not different among groups. Average symptom severity scores decreased about 30 points in each group. Return to usual activities averaged 0 days (interquartile range, 0e14 days) for hysteroscopic myomectomy, 21 days (interquartile range, 14e28 days) for laparoscopic myomectomy, and 28 days (interquartile range, 14e35 days) for abdominal myomectomy. After propensity adjustment, quality of life outcomes in the laparoscopic and abdominal myomectomy groups were similar except for more anxiety in the laparoscopic myomectomy group and slightly more pain in the abdominal myomectomy group. After propensity weighting, return to usual activities favored laparoscopic compared to abdominal procedures; median time was the same at 21 days, but the highest quartile of women in the abdominal group needed an additional week of recovery (interquartile range,14.0e28.0 for laparoscopic versus 14.0e35.0 for abdominal, P < .01). Time to return to work was also longer in the abdominal arm (median, 22 days; interquartile range, 14e40 days, versus median, 42; interquartile range, 27e56). CONCLUSION: Women who underwent myomectomy had substantial improvement in health-rel...

Efficacy and Safety of the Two Ayurveda Drug Regimens in Uterine Fibroids: A Randomized Single-Blind Clinical Trial

“…Demographic data were not significantly variable in the three arms ( Table 2 ). Therefore, a comparable study can be made in this research' findings where most of such other studies were unable to perform [ 15 ].…”

Breast, Ovarian, and Uterine Cancer: Etiology, Pathophysiology, and Management- A Review

“…The first category consisted of women undergoing hysterectomy for fibroids and the other category consisted of women undergoing hysterectomy for genital prolapse. It was observed that women belonging to the first category showed a 29% risk of uterine cancer, whereas women in the second category showed a 0.1% increase in the risk of uterine cancer 86 .…”

Choice of primary and secondary outcomes in randomised controlled trials evaluating treatment for uterine fibroids: a systematic review

“…may experience dyspareunia, 38% pelvic pain requiring analgesia and 62% urinary frequency symptoms. 2 The Uterine-Fibroid Symptom Severity and QoL validated questionnaire was the most commonly used QoL outcome instrument. 92 This metric provides a composite assessment of symptoms, but overwhelmingly prioritises bleeding symptoms over pain and bulk-related symptoms.…”